Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported promising outcomes from its Phase 2b SEISMiC Extension Study, showcasing the potential of istaroxime in managing early cardiogenic shock caused by …
Windtree Therapeutics Announces Promising Results for Heart Failure Drug Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a significant milestone in its Advance-HTN trial by hitting its enrollment target of 261 participants. This pivotal trial is crucial in …
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial Read More
MALVERN, PA — YPrime has been recognized as a Trailblazer in the Everest Group’s Clinical Trial Patient Engagement Products Assessment. This accolade highlights YPrime’s dedication to enhancing patient participation and engagement …
YPrime Honored as Trailblazer in Clinical Trial Patient Engagement Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently unveiled a draft guidance designed to enhance multiregional clinical trials (MRCTs) in oncology, aimed at improving data relevance for …
FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and Phase 2 studies at the International Congress for Ataxia Research …
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis Read More
PHILADELPHIA, PA — Passage Bio, Inc. has unveiled promising interim data from its ongoing global Phase 1/2 upliFT-D clinical trial at the 14th International Conference on Frontotemporal Dementias (ISFTD2024). The study …
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia Read More
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has unveiled promising data from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in treating plantar fibromatosis, presented at the American Orthopaedic …
Endo, Inc. Highlights Promising Study Results for Plantar Fibromatosis Treatment Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced encouraging interim results from its global Phase 1b FURTHER trial, presented at the prestigious IASCLC 2024 World Conference on Lung …
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC Read More